INVENTIVA ADS/1 O.N. Total Assets
INVENTIVA ADS/1 O.N. total assets. Based on the latest financial reports, INVENTIVA ADS/1 O.N. (6IVA) holds total assets worth €249.51 Million EUR (≈ $291.70 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 6IVA market cap for the company's overall valuation and market capitalisation.
Total Assets of INVENTIVA ADS/1 O.N. (2021–2025)
Total assets of INVENTIVA ADS/1 O.N. from 2021 to 2025. This chart illustrates how INVENTIVA ADS/1 O.N.'s total assets have evolved over time, based on quarterly financial data. See 6IVA stock price and chart for real-time trading data and today's change.
INVENTIVA ADS/1 O.N. - Asset Composition Analysis
INVENTIVA ADS/1 O.N. Total Assets Breakdown (December 2025)
INVENTIVA ADS/1 O.N. total assets breakdown as of December 2025. INVENTIVA ADS/1 O.N.'s total assets of €249.51 Million consist of 98.0% current assets and 2.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 39.8% |
| Accounts Receivable | €2.02 Million | 0.8% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €183.00K | 0.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how INVENTIVA ADS/1 O.N.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore INVENTIVA ADS/1 O.N. (6IVA) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: INVENTIVA ADS/1 O.N.'s current assets represent 98.0% of total assets in 2025, an increase from 94.8% in 2021.
- Cash Position: Cash and equivalents constituted 39.8% of total assets in 2025, down from 71.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
INVENTIVA ADS/1 O.N. Competitors by Total Assets
Key competitors of INVENTIVA ADS/1 O.N. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
INVENTIVA ADS/1 O.N. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.16 | 0.92 | 0.59 |
| Quick Ratio | 3.16 | 0.92 | 0.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €167.09 Million | €-9.22 Million | €-19.54 Million |
INVENTIVA ADS/1 O.N. - Advanced Valuation Insights
This section examines the relationship between INVENTIVA ADS/1 O.N.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.02 |
| Latest Market Cap to Assets Ratio | 3.84 |
| Asset Growth Rate (YoY) | 109.7% |
| Total Assets | €249.51 Million |
| Market Capitalization | $957.19 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values INVENTIVA ADS/1 O.N.'s assets at a significant premium (3.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: INVENTIVA ADS/1 O.N.'s assets grew by 109.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for INVENTIVA ADS/1 O.N. (2021–2025)
The table below shows the annual total assets of INVENTIVA ADS/1 O.N. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €249.51 Million ≈ $291.70 Million |
+109.73% |
| 2024-12-31 | €118.97 Million ≈ $139.08 Million |
+71.03% |
| 2023-12-31 | €69.56 Million ≈ $81.32 Million |
-40.04% |
| 2022-12-31 | €116.00 Million ≈ $135.62 Million |
-4.90% |
| 2021-12-31 | €121.98 Million ≈ $142.61 Million |
-- |
About INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more